Evidence map›Paper›PMID 42330494›Full record

ArticleCancer immunology research2026

Cancer-Intrinsic Protein Neddylation Modulates the Intratumoral Immune Landscape to Constrain Immune Checkpoint Blockade Therapy.

Irineos Papakyriacou, Yonglin Lu, Malin Jarvius, Maris Lapins, Jordi Carreras-Puigvert, Yumeng Mao

Abstract read
In one paragraph

Article in Cancer immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Irineos PapakyriacouDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-0728-0995
Yonglin LuDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0009-0003-6692-437X
Malin JarviusScience for Life Laboratory , Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-1565-6155
Maris LapinsScience for Life Laboratory , Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-0122-6680
Jordi Carreras-PuigvertScience for Life Laboratory , Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-7671-3707
Yumeng MaoDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-6142-6628

Funding

Cancerfonden (Swedish Cancer Society) 220474JIACancerfonden (Swedish Cancer Society) 232656PjRoyal Swedish Academy of Sciences (KVA) ME2024-0042Science for Life Laboratory (SciLifeLab) SLL2019/9Swedish Foundation for Strategic Research FFL21-0043Vetenskapsrådet (VR) 2022-01461
6 · The paper itself

Abstract

The cancer-intrinsic network controlling the response to immune checkpoint blockade therapy remains elusive. Using a published single-cell RNA sequencing (scRNA-seq) dataset from patients with breast cancer, we found that pretherapy mRNA expression of NEDD8, which encodes the regulatory protein essential for neddylation, in cancer cells was negatively associated with T-cell expansion upon pembrolizumab treatment. Genetic ablation of protein neddylation in murine tumors induced a curative response to PD-1 or PD-L1 blockade in mice. Combined analysis of neddylation-deficient murine tumors using scRNA-seq and high-resolution spatial transcriptomics revealed distinct spatial immune co-localization and immune cell signatures. In a high-content phenotypic screen of known compounds, protein neddylation was required for the induction of phenotypic changes by lipid inhibitors and ferroptosis inducers in human breast cancer cells. In accordance, these compounds enhanced the efficacy of PD-1 blockade and protected mice from tumor rechallenge. Altogether, we delineate the unknown functions of protein neddylation on antitumor immunity and provide therapeutic options that can enhance immunotherapy.

Indexed as

Breast NeoplasmsImmune Checkpoint InhibitorsNEDD8 ProteinAnimalsCell Line, TumorFemaleHumansMiceProgrammed Cell Death 1 ReceptorTumor MicroenvironmentImmune Checkpoint InhibitorsNEDD8 ProteinNEDD8 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID42330494
PMCPMC13535320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.